Introduction
The prostate cancer (PCa) landscape has been transformed over the past decade with a focus on limiting overdiagnosis and reducing overtreatment. In particular, the use of mainstay curative treatments, such as radical prostatectomy (RP) and radiotherapy, for low-risk men has been questioned because of the significant morbidity, 1 quality-of-life impact, 2 and economic burden 3 associated with these treatments. PCa care has been further transformed by the emergence of active surveillance, which aims to delay or prevent treatment by closely monitoring disease progression. Active surveillance is an effective option for men with localized PCa 1 and, encouragingly, active surveillance uptake from a statebased registry of Australian PCa patients has been shown to be higher than in many international registries. 4 Widespread prostatespecific antigen (PSA) testing has resulted in increased PCa detection, as well as a 'stage migration' towards an earlier diagnosis and a reduced incidence of metastatic disease. 5, 6 This has led to growing concern for the overdiagnosis in younger men at low risk of clinically significant disease 7 and older men at low prostate-specific mortality risk. 8 Despite these transformations in PCa care, a majority of men with newly diagnosed PCa undergo some form of curative treatment, regardless of their disease risk. 5 Additionally, studies examining the impact of uro-oncology multidisciplinary meetings over the past decade have suggested a favoring of aggressive interventions for PCa management. 9, 10 This includes a greater volume of high-dose-rate (HDR) brachytherapy, 10 which is used primarily as 'boost' therapy [with either external beam radiotherapy (EBRT) or surgery] for higher-risk PCa than what is typically treated with low-dose-rate (LDR) brachytherapy. 5 Furthermore, there is the potential for an increased uptake of pelvic lymph node dissection (PLND), the most reliable and accurate staging method for prostate cancer metastases. 11 Therefore, the objective of our current study was to analyze for temporal trends in these key indicators of PCa care, in particular, the rates of screening and aggressive interventions for PCa.
Materials and methods

Study population
The study population consisted of all Australian men who underwent a screening PSA test, RP, or brachytherapy for PCa between 2001 and 2014. The study period commenced from when a dedicated PSA screening test was first incorporated into the Australian Government's Medicare Benefits Schedule (MBS) in 2001.
Data selection
A number of studies have analyzed the impact of uro-oncology multidisciplinary meetings on PCa management decisions over the past decade. Notable trends have been: (1) a shift towards greater active surveillance of lower risk disease; 10 and (2) the utilization of aggressive interventions, such as HDR brachytherapy. 9, 10 The present study uses health services data to analyze trends in PSA screening and aggressive interventions. Future registries will be able to account for the number and characteristics of men on active surveillance. 12 
Data extraction
Data on services defined by specific item numbers were sourced from the MBS website. 13 This captures all tests and treatments performed in the community. Delivery of HDR brachytherapy to the prostate uses the MBS billing code of '37227' and was first introduced to the MBS in 2007. HDR brachytherapy must be performed 'by a urologist or radiation oncologist' in 'association with a radiation oncologist', with no limitations on tumor staging or grade. Counts of HDR brachytherapy include both the insertion and removal of catheters for radiation delivery. Seed implantation of low-dose-rate brachytherapy has been billed under code '37220' since 2001, and must also be performed in 'association with a radiation oncologist'. LDR brachytherapy is restricted to patients with localized PCa, Gleason 7 (Gleason 6 prior to 2008) and PSA 10 ng/mL at the time of diagnosis. Only LDR brachytherapy data from 2007 were analyzed to enable comparisons with HDR brachytherapy over the same time period. A dedicated item code ('66655') for an initial 'screening' PSA test was introduced in 2001 and is defined as a single PSA test performed during a 12-month period in previously undiagnosed prostatic disease. Radical prostatectomy with 'sparing of nerves around the bladder and bladder neck reconstruction' is billed under code '37211' when PLND is performed or '37210' when PLND omitted. Both RP item codes were introduced prior to 2001. EBRT was excluded from this study because of different radiation field settings and dosimetry, along with poor capture of the actual treatment received when using MBS item codes.
14 All population data were obtained from the Australian Bureau of Statistics. 15 
Statistical analysis
Age-specific rates of PSA-based screening were calculated from 2001 to 2014. Trends of annual change in PSA screening rates from 2008 were analyzed using Cuzick's nonparametric test for trend. Mean 7-year ratios (2001e2007 and 2008e2014) of RP with PLND compared to RP without PLND were determined for state jurisdictions. Annual ratios of HDR brachytherapy to LDR brachytherapy were determined for state jurisdictions from 2007. 
Results
Radical prostatectomy
PSA screening tests
PSA screening rates have been highest for patients aged 65e74 years (an annual average of 21,453 per 100,000 men) and 55e64 years (19, 575 per 100,000 men) from 2001 to 2014, which together accounted for 56% of all screening tests over this period (Fig. 3) . The next highest screening rates were for patients aged 75e84 years (15,793 per 100,000 men), 45e55 years (12,315 per 100,000 men) and 85 years (8,064 per 100,000 men). From 2008, PSA screening rates trended downward significantly year-to-year for all ranges (P < 0.02) except for men aged 85 years (P ¼ 0.56), and excluding a small aberrant rise in 2011.
Discussion
The key findings of this population-based analysis are that a considerable decline in PLND and HDR brachytherapy rates occurred over the study period. This trend was observed across all Australian states and territories, excluding brachytherapy rates in the Australian Capital Territory. Together these results indicate that fewer Australian men are undergoing aggressive interventions for PCa. Previous United States (US) studies 16, 17 have observed a similar decline in PLND rates and this was attributed to stage migration and an improved ability to risk-stratify patients before surgery. Stage migration of PCa that has been observed in a number of Australian studies 5,6 is a highly feasible explanation for our result. We suspect that more patients are being diagnosed with organ-confined and lower risk disease as a result of PSA testing, which has reduced the need for aggressive interventions. Risk-stratifying tools, or nomograms, that are based on routinely available preoperative variables have been shown to better identify men at risk of nodal disease 18 and are currently used in Australian institutions. 19 Notably, many of these risk-stratifying tools are based on a limited PLND, which may underestimate the incidence of positive nodes, and none have had oncologic efficacy verified with a prospective randomized clinical trial.
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In the past few decades, PCa treatment planning has become more complicated and contentious owing to the proliferation of treatment options and an absence of high-quality evidence supporting one method over another. 2 Consequently, multidisciplinary teams often decide on and coordinate clinical treatments, 9 which may involve a number of modalities for an individual patient. Technical advances and the publication of trial results are two major reasons multidisciplinary clinicians will choose to treat pelvic nodes and to recommend particular therapies. 20 Brachytherapy has been an established technique since the commencement of our study period. Conversely, prostate surgery has seen the rapid adoption of a minimally invasive, robot-assisted technique. Currently it is unclear to what effect a shift from an open to a minimally invasive approach has had on the use of PLND. 21, 22 Surgeon experience is one important determinant for the likelihood of performing PLND, irrespective of the surgical approach, and this likely reflects the increased risk of complications with PLND, such as lymphedema, lymphocele, deep vein thrombosis, and pulmonary emboli. 21 Although local registry and health services data have shown that RP incidence is rising for Australian populations, 5, 23 to our knowledge, patterns of PLND have not previously been explored. We found that PLND rates during prostate surgery greatly varied amongst Australian state jurisdictions despite overall widespread reductions. For example, between 2008 and 2014, PLND rates in NSW and the ACT were nearly three times higher than in other jurisdictions. A subanalysis has shown that PSA screening rates in NSW and ACT over this same period were within 10% of the annual national average. Hence, the elevated PLND rates in NSW and ACT compared to other jurisdictions were not simply due to these states performing less screening and therefore treating higher-risk PCa. More plausible explanations include the dissemination of robotassisted technology, as well as variable involvement of multidisciplinary teams and the adequacy and/or access to radiotherapy centers. 24 HDR brachytherapy uses a high dose of radioactive seeds ( 12 Gy/h) that can only be placed temporarily, compared with permanent seed placement in LDR brachytherapy. Since 2007, we have found a shift towards much lower use of HDR brachytherapy relative to LDR brachytherapy. By 2014, all state jurisdictions, except ACT, had a ratio of HDR to LDR brachytherapy of < 0.5. Previous Australian registries have shown that HDR brachytherapy is a minor contributor to overall PCa care 2, 5 and is used as either adjunct therapy to androgen deprivation therapy or as boost therapy with EBRT or surgery. 5 Currently, HDR brachytherapy has not been tested in sufficient numbers to be recommended as monotherapy. 11 Importantly, dosing and fractionation for HDR brachytherapy is inconsistently delivered across Australian radiotherapy departments, 25 which is unsurprising since no Australian guidelines exist and there is no clear consensus amongst international brachytherapy societies. 26, 27 Another important finding of our study was that PSA-based screening rates have significantly declined since 2008 in all age groups except for men aged 85 years (excluding a small aberrant rise in 2011). Two large randomized trials have reported that mass PSA-based screening offers limited benefit or no benefit over usual care. 28, 29 Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) showed screening did not affect allcause mortality after 11 years of follow-up but did show a reduced incidence of advanced disease and prostate-specific mortality in men aged 55e69. 29 Thus far, urological societies have discouraged widespread population screening but have endorsed a role for opportunistic screening of men aged 55e69. 11, 30, 31 We found that the majority of screening tests are conducted in men aged 55e74 and this potentially reflects the uptake of opportunistic screening. It is possible that the publication of the two major trials questioning the benefits of screening and the resultant publicity afforded to these studies 32 have contributed to the reduction in screening rates. Negative media reporting conceivably has alerted patients to the limitations of screening and thereby influenced their willingness to participate. 32 Men aged 85 years may not have the same access to contemporary online media sources, which potentially explains the unchanged and unnecessarily high screening rates amongst this age group. Another feasible explanation for the reduction in screening rates in most age groups is the penetrance of regional 30 and key international guidelines 32 such as the US Preventive Services Task Force. It will be interesting to see in time whether the decline in PSA-based screening rates we recorded for most age groups leads to a reversal of stage migration, such that rates of advanced disease return towards pre-PSA era levels. We could not be certain from the data available to us whether patients undergoing PSA-based screening were asymptomatic or at high suspicion for PCa (such as suspect digital rectal exam or family history). A previous study of Australian men undergoing PSA-based screening reported minimal prior symptoms for the majority of men, suggesting that these may be true screening tests. 33 It is possible that incorrect item numbers were used for brachytherapy (HDR or LDR) and prostate surgery (with or without PLND) in some proportion of our data. It is also possible that PSA screening tests were misclassified as monitoring or follow-up tests, each of which have different item numbers. Medicare Australia performs 'coning' of multiple pathology items, whereby only the three most costly items are reimbursed and recorded. 8 Due to this approach, we may have underestimated the true number of PSA screening tests. Combination therapy is not currently recorded through health services data and we suspect that androgen deprivation therapy with HDR brachytherapy is widely used but not reported. Since Medicare data does not presently capture the type of prostatectomy approach, further studies are needed to determine if PLND rates differ with a minimally invasive approach compared to a conventional open prostatectomy. Additionally, we are unable to exclude data for RPs (with or without PLND) performed in conjunction with radical cystectomy for an invasive bladder tumor. A separate analysis of radical cystectomy (MBS billing code '37014') has revealed 3,190 procedures were recorded for male patients between 2001 and 2014, which would account for < 5% of all RPs over this period. We did not examine rates of focal therapy (not presently reimbursed by Medicare) or EBRT, which is poorly captured with Medicare data.
14 Notably, this study does not account for all men undergoing aggressive interventions over the study period because both androgen deprivation therapy (ADT) and EBRT can also be used for higher risk disease. Our study has biases inherent with observational data. Although Medicare data have been validated to provide a true account of prostate surgery and brachytherapy, accuracy can be improved when combined with local registries.
14 Local registries also enable patient characteristics and cancer staging to be linked to the treatment outcomes of PLND and HDR brachytherapy. An upto-date analysis of clinical-decision making for aggressive interventions, including the recommendations from multidisciplinary clinicians and use of risk-stratifying tools, as well as a patient's beliefs and anxieties, would make a useful adjunct to our study. Future studies should examine why PSA-based screening rates remains relatively high among older men in Australia, particularly because no specific guidelines currently exist for managing a positive screening result in this age group. 34 In conclusion, rates of PLND and HDR brachytherapy have declined in Australia, which provides evidence for the effect of stage migration from widespread PSA screening. Currently, PSA screening rates among older men remain proportionately high, which potentially exposes them to unnecessary investigations and treatment. Our results reveal that contemporary approaches to prostate surgery vary among jurisdictions and further investigation is warranted to understand the clinical decision-making process behind overall and regional trends.
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